<DOC>
	<DOCNO>NCT00000895</DOCNO>
	<brief_summary>The purpose study determine infection Mycobacterium avium complex ( MAC ) occur part body find blood . This study also evaluate relationship amount HIV blood , immune system function , presence MAC infection . HIV-positive patient risk MAC infection immune system weaken HIV . It hop aggressive treatment anti-HIV drug may improve immune system enough prevent MAC .</brief_summary>
	<brief_title>A Study Learn More About MAC Disease Use Anti-HIV Drugs Patients With Advanced HIV Infection</brief_title>
	<detailed_description>The intent study define precisely natural history immunopathogenesis MAC disease HIV-infected population . It suggest MAC disease AIDS patient result specific immunologic deficiency cause HIV infection host result specific mycobacterial virulence property . Therefore , aggressive antiretroviral drug treatment HIV-infected patient risk DMAC due specific immune deficiency improve immune function manner resist DMAC . A total 85 patient stratify baseline one three group : Group I - 40 patient high risk MAC infection neither follow beyond baseline receive study treatment . Group II - 15 patient DMAC , i.e. , newly diagnose MAC-bacteremic patient 72 hour prior treatment MAC , receive individualize regimen HAART 48 week : nelfinavir ( NEV ) , nevirapine ( NVP ) , nucleoside reverse transcriptase inhibitor ( ) per primary physician . Patients evaluate clinical , microbiologic , virologic assessment , intensive immunologic evaluation Weeks 12 , 24 , 48 . Group III - 30 asymptomatic HIV-infected patient stratify ( 15 patients/stratum ) CD4 count ( less equal 50 cells/mm3 100-250 cells/mm3 ) . Patients Group III follow HAART regimen evaluation Group II patient continue evaluation 48 week , acceptable response find within 12 week entry . Patients Stratum 1 Group III receive MAC prophylaxis azithromycin weekly follow-up evaluation Group II . Patients Group III positive MAC blood bone marrow culture time study , point , follow schedule evaluation patient Group II . [ AS PER AMENDMENT 11/3/98 : Up 100 evaluable patient study . Group 2 modify include additional 15 evaluable patient know MAC bacteremia less equal 7 day prior MAC treatment unable commit long-term follow-up ( Group 2b ) ; patient undergo baseline evaluation . Group 2a consist 15 evaluable patient know MAC bacteremia less equal 7 day prior MAC treatment willing able enter follow-up phase . ]</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Opportunistic Infections</mesh_term>
	<mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria You may eligible study : Are HIVpositive . Have CD4 count 50 cells/mm3 100 250 cells/mm3 within 30 day study entry . Have least one symptom ( e.g. , fever , diarrhea , weight loss ) suggestive MAC infection . Have MAC infection 7 day less MAC treatment . Have HIV blood level great 10,000 copies/ml within 30 day study entry . Are 18 year age old . Exclusion Criteria You eligible study : Have active infection ( except MAC Group 2 patient ) cancer . Are unable follow acceptable antiHIV drug regimen ( Groups 2 3 ) . Are pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Mycobacterium avium-intracellulare Infection</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Mycobacterium avium Complex</keyword>
	<keyword>Bacteremia</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Risk Factors</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>